MØD VORES VIRKSOMHEDER
Nogle af de mest lovende nye biotek- og life science firmaer i Danmark, er placeret i COBIS. Højtuddannede, professionelle, og inspirerende at være omkring - de er hjertet af forskerparken og sandsynligvis den vigtigste grund til, at du bør overveje at vælge COBIS. Mere end 85 virksomheder har allerede valgt os - du kan være den næste.
Her på siden kan du læse lidt om de virksomheder som bor hos COBIS i øjeblikket. De har hver især skrevet lidt om dem selv, så du får en ide om hvad de arbejder med. Mød vores virksomheder her og gå ud og snak med dem, hvis du finder dem spændende. Det er ikke sikkert de har et job endnu, men sparring og erfaringer med at være iværksættere / start-ups har de masser af.
Nogle af disse virksomheder er dog flyttet ud, hvilket er glædeligt, for så vokser de og giver plads til nye virksomheder hos COBIS. Fremskridt er godt og vi holder øje med udviklingen hos hver enkelt virksomhed.
Acesion Pharma is a Danish biotech company founded in 2011 by Morten Grunnet and Ulrik Sørensen and based on seeding capital from the venture funds Novo Seeds and SEED Capital Denmark. Acesion Pharma aims to develop more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. AF mainly affects the elderly population and often causes a pronounced decrease in quality of life and furthermore increases the risk of stroke. Existing drug therapies generally have a limited efficacy and/or are associated with risk of serious adverse events. Therefore, there is a considerable need for developing better and safer drugs. Inhibition of SK channels, an ion channel present in the heart and with relevance for the cardiac rhythm, constitute a novel and promising drug target for the treatment of AF. Acesion Pharma aims to develop a first-in-class SK channel inhibitor for the acute cardioversion of AF.
aCROnordic Health Claim Services support the development of Health Claim products from pharma, biotech, medical device or nutraceutical companies. aCROnordic is your - Single Point of Contact - Contract Research Organization providing services through highly qualified partners, utilizing global cost efficient resources, connected through a unique infrastructure.
Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro is managed by professionals experienced in drug discovery and development. By acquiring lead compounds through collaborations and partnerships, Avineuro develops novel products and extends the reach of marketed compounds for indications with a significant commercial potential. Avineuro emphasizes a rational approach that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.
Axxam S.p.A is an innovative Partner Research Organization (iPRO) providing science-driven, top quality and tailored Discovery Services.
Axxam expertise includes:
- Molecular biology: cloning and construct preparation, automated gene expression screenings (Taqman-based), protein expression, gene editing
- Cell-line generation: GPCRs, ion channels, nuclear hormone receptors, transporters & others
- Assay development: Biochemical assays (protein interactions & enzymes) and Cell-based assays including optogenetics biosensors
- Natural and synthetic compound libraries
- High-Throughput Screening automated platforms: fluorescence, luminescence & radiometric
- High-Content Screening automated platforms
- Compound management and Storage
- Hit characterization & profiling
- H2L activities, Cardiac safety and liability profiling
- Electrophysiology (Manual & Automated Patch Clamping)
With more than 16 years of experience, Axxam has successfully conducted hundreds of Hit identification projects, Hit-to-lead activities and Lead optimization programs.
Axxam works with Clients globally and deals with projects from different market segments: Pharma, Biotech, Academia, Crop protection, Animal health, Cosmetics, Fragrances, Flavors and Nutrition.
BGI was founded in 1999 as a nonprofit research organization to support the Human Genome Project. Over the years, BGI has grown into a multi-national genomics company with significant global operations, including sequencing laboratories based in the US, Europe, Hong Kong and mainland China.
BGI Europe’s headquarters were established in Copenhagen, Denmark, in 2010. Our experience in high-capacity, high- throughput analytics, bioinformatics capabilities, and our long history in large population–scale genomics and data analysis, means that BGI Europe is uniquely positioned to support both academic institutions and pharmaceutical companies with a wide array of high quality genomic services for basic research, pharmacogenomics and clinical diagnostics.
BioCare Copenhagen is a Danish bioscience company that specialises in microbial actives targeting gastrointestinal disorders, metabolism, infections and immunity.
The company’s activities are based on research conducted by Copenhagen University Hospital, Denmark’s leading hospital for patients requiring highly specialised treatment. BioCare Copenhagen was established as a joint venture between the Danish Ministry for Science, Technology and Innovation and the management team Søren B. Thomsen (CEO) and Jesper Gantzel (COO).
Offering innovative products with a strong competitive edge, BioCare Copenhagen and its partners have achieved a very robust market position on several European markets, including the Danish home market, reaching a market share of 70% in probiotic supplements. Furthermore, the company has been awarded with the Danish Gazelle price 2016 due to its continuously growth the previously four years.
What does it take for a life-science researcher to start a company? How do you bring science out of the lab and into the economy?
The BioInnovation Institute offers entrepreneurs and researchers in life science help to bring interdisciplinary ideas to life and research to market. Through providing networks, support, facilities, and funding.
BII embraces every phase of a life-science start-up company and though we are based in Denmark, our aspirations are international. BII is a Novo Nordisk Foundation initiative.
Anne-Marie Lund Winther and William Brown
Catalyze is passionate about innovation, research and development in biotech and life sciences that will change the world. That is why Catalyze enthusiastically works with leading researchers and developers to obtain funding, enabling them to achieve their goals.
Catalyze proudly supports leading researchers and ambitious innovators with grand ideas, working with projects in early stage research, all the way through the stages of development utilizing a non-dilutive funding, loans and venture capital which is specifically tailored to the individual plans of each project.
In the past few years, Catalyze has grown immensely broadening its network of partners significantly (1,000+ in Europe and beyond) which is utilized as a vital factor in the success of projects. These partnerships assist a company by increasing its chances of raising funds. This has resulted in raising close to half a billion Euro in funding for its clients during this time.
With an unparalleled amount of experience and a proven track record in providing our clients funding through grants and subsidies such as HORIZON2020, Eurostars, NIH, EuroTransBio and more regional funds and patent organizations, Catalyze will be expanding its strategic position within and beyond Europe. Long lasting relationships are built on maintaining a high standard of quality and client focus with the intention to continue providing services to an ever-increasing number of innovative organizations in consulting and executing the optimal strategies.
Catalyze by entrepreneurs, for entrepreneurs.
Clinical Survey Outcomes
Clinical-Microbiomics is an independent contract research organization fully dedicated to microbiome research. We provide world-leading end-to-end microbiome research services within human, animal and plant / soil microbiomes. From clinical trial consulting to sequencing and complex bioinformatics with integration of other meta-‘omics data, we partner with you to provide actionable microbiome insights from your studies.
Contera Pharma identifies and develops innovative treatments for patients suffering from movement disorders. We use our expertise in drug discovery and development in close collaboration with expert individuals and organizations to provide foundations for succes.
Copenhagen Capacity is the Danish capital city region’s official organisation for investment promotion, business development and cluster growth.
Copenhagen Capacity guide companies through all phases of partnering, market entry and clinical development in Medicon Valley.
Copenhagen Life Science Advisors
Copenhagen Life Science Advisors is a network of life science professionals with years of experience from pharmaceutical, biotech and medtech industries, as well as experience in working in and with life science venture capital. We work together as one, offering services in commercialization of science and fundraising of early stage companies.
Daiichi Sankyo Oncology Nordics
Daiichi Sankyo and its 15.000 employees in more than 20 countries are dedicated to the creation and supply of innovative pharmaceutical products. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, the Group’s 2025 vision is to become a “Global Pharma Innovator with Competitive Advantage in Oncology”. Our European headquarters are in Munich, Germany and we have affiliates in 12 European countries. For more information: www.daiichi-sankyo.eu.
Dania er et konsulenthus dedikeret til Sundhedssektoren . Vores ydelser omfatter projektledelse, koordinering og analyse indenfor:
- Sundheds IT
- Organisering og planlægning
- Registering og afregning
- Data og styring
- Strategi og ledelse
Kontakt Partner Andreas Schroll, tlf. 27104321, hvis du vil høre mere om samarbejdsmulighederne.
Danish-Chinese Organic Food Center
DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and production in Denmark and perform common business interests in this context, both nationally and internationally. DANISH BIOTECH members are private companies in Denmark who research, develops or produces pharmaceuticals or other products with a significant content of biotechnology (biotech companies) and their parent companies and investment funds that are active owners of biotech companies. Membership can be obtained on www.danskbiotek.dk.
Defensin Therapeutics is a Danish biopharmaceutical company spun out from Novozymes A/S in 2013. Defensin Therapeutics focuses on the development and commercialization of novel products for the treatment of diseases and conditions associated with dysregulation of the human microbiota.
ESS Data Management and Software Centre
The European Spallation Source (ESS) ERIC is a multi-national collaboration that is currently constructing the world’s brightest neutron scattering research facility in Lund, Sweden. The Data Management and Software Centre (DMSC), located in Copenhagen, Denmark, is an ESS Division that is responsible for developing the data acquisition, reduction, visualization and analysis software for the ESS neutron beam instruments, and for storing, and making available, the scientific research data taken at the ESS when it is operational.
The ESS will be up to 100 times brighter than today’s leading neutron scattering facilities, enabling new opportunities for researchers in the fields of life sciences, energy, environmental technology, cultural heritage and fundamental physics.
Fischer BioConsult provides services relating to financing, business development and product development within the biotech sector. Per Fischer has more than 15 years experience from biotech, pharma and consulting, and has worked for more than 25 clients over a period of 4 years.
Gabather (GABA Therapeutics) fokuserer på stærkt potente, selektive GABAA-receptormodulatorer, designet ved hjælp af proprietær farmakoforemodellering med lægemiddelkandidater i præklinisk og klinisk udvikling, såsom antipsykotika, antidepressiva, anxiolytika, analgetika, kognitionsforstærkere, til behandling af CNS-sygdomme med højt umættet behov.
Galecto Biotech is a newly founded company, focused on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases. The company's products target galectins, a group of proteins that play important roles in many disorders. Galecto Biotech's high potency galectin modulators may open new treatment possibilities for many patients.
Genau & More
Genau & More operates in the regulated industries Pharma, Biotech, and Medical Device and are offering quality oriented consultancy within e.g. current compliance, validation, and business performance – services that will ensure the inspection readiness of the clients and ultimately help to ensure patient safety in medical treatment.
An Asia-Pacific, full service contract research organisation (CRO).
At GreenLight Clinical we strongly believe that effective healthcare is enabling – both for individuals and the communities they live in. Translating innovative discoveries, through clinical development, into novel and accessible medical therapies is fundamental to achieving better health outcomes for patients. With our experience in expediting pharmaceutical and biotech drug development we aim to ensure that the transition from test-tube to product is achieved efficiently. To do this, we favour customised strategies, often adopting cutting edge technology-based solutions, and we thoughtfully integrate our capabilities with the existing strengths of our partners to achieve smarter, faster results.
Hedia er en intelligent og personlig app for diabetikere. Den guider til en vejledende insulindosis udregnet på baggrund af blodsukker, fysisk aktivitet og indtag af kulhydrat. Hedia bliver over tid klogere på den enkelte diabetiker og kan derfor forudse tendenser samt varsle om et forestående højt eller lavt blodsukker.
At HPNow, we believe that natural solutions are often the best. That is why we are introducing a novel technology solution for the on-site generation of a powerful, yet safe and eco-friendly water and air treatment agent. Our on-site generation devices produce pure hydrogen peroxide where and when it is needed using only water, air and electricity as input. These can be utilized in water treatment applications ranging from irrigation, livestock, aquaculture, municipal, residential, and through to chlorine-free swimming pool, as well as in air and surface treatment applications.
ISD-Immunotech is developing a STING pathway modulator as a first-in-class treatment for Systemic Lupus Erythematosus (SLE) and other autoimmune diseases where the STING pathway is clearly shown to be implicated in the pathogenesis of the disease. ISD is a spin-out of Aarhus University and is run by a team of experienced pharmaceutical experts and business leaders with a solid track record of successful drug development.
IWA Consulting – For quality, safety, and efficacy
The IWA Consulting Team is a dedicated group of regulatory affairs specialists providing expert services to a range of international private and public clients. We do that based on our long term regulatory experience, in-depth knowledge, and expertise.
We assist biotech, pharma, and medtech companies in achieving their major regulatory milestones, knowing and thoroughly understanding the sense of urgency that applies to this business area. Regulatory affairs – in every aspect of the discipline – is our core competence.
Jusmedico is a specialist law firm providing legal services to the biotech, pharmaceutical, medical device, dentistry and veterinary industries, life science investors and to suppliers and service providers thereto.
The working areas of Jusmedico include, without limitation, biotech start-ups, capital raising and re-funding activities, research & development, pre-clinical test (GLP) and clinical trial (GCP), manufacturing & supply (GMP), labeling & packaging, licensing, marketing alliances (co-promotion & co-marketing), agent and distribution agreements (GDP), advertising & promotion, pricing & reimbursement, parallel imports of pharmaceuticals and insurance issues related to all of said working areas, including product liability claims.
Internationally, Jusmedico is a founding member of the BioLawEurope Alliance comprising a network of independent European law firms and individual attorneys providing legal services in the same fields as Jusmedico. Further, Jusmedico operates a representative office in New York, USA.
Jusmedico is regulated by the Danish Bar and Law Society and is audited by Ernst & Young LLP, Copenhagen
Keep Your Promise
- Steer and drive projects forwards
- Professional clinical study protocols, investigators brochure’s, clinical study reports and other regulatory documents which ensure you licence to operate.
- Plan and effectuate production of clinical modules for NDA etc.
- Coordinate and prepare response to HA questions
- Efficient writing of briefing packages to support meeting requests
LBKPATENT is focusing on providing IP, in particular, Patent consulting to Pharmaceutical companies, Biotechnology companies having focus within the life science area, such as therapeutic area as well as start-up companies having focus within the life science area. LBKPATENT is also able to provide patent consulting within the broader chemistry area, as well as mechanical area. Patent consulting includes without limitation drafting and prosecuting patents, as well as analysis of patentability and freedom to operate, and developing patent strategies.
Life Science Plus Advokater
LIFE SCIENCE PLUS Advokater provides specialized and business oriented legal advisory based upon more than 15 years of hands-on experience from the Life Science industry - both from an operational and strategic level.
* General Legal Services - full spectrum of general commercial & R&D specific contracts, legal risk management, IP aspects as well as commercially oriented legal and strategic advice and compliance work.
* Business Development/Licensing activities - coordination and structuring of licensing and other transactional activities, incl. due diligence processes, deal structures, drafting and negotiation as well as anchoring/integration.
* Partnerships - structuring, drafting, negotiation and management of value creating partnerships & alliances with e.g. academia, institutions and commercial partners; R&D outsourcing and CRO vendor management.
We also help companies to professionalize operations and governance to prepare them for external fundraising.
The LINX Association is the platform for Linking Industry to Neutrons and X-rays.
LINX is the focal point for creating commercial value through innovative material science solutions based on advanced neutron & X-ray technology in collaboration with facilities, such as MAX IV, ESS and European XFEL.
The LINX Association was established in spring 2016 to encompass “The LINX Project” funded by the Danish Innovation Fund (IFD) for a period of 5 years (2016-2021).
Medidee was established by three partners, all experts in the field of medical devices. As professionals with a multidisciplinary background we provide all necessary competences internally to handle all aspects of your project, from the Design to the Certification. Our team is expending regularly to provide the best resources and competences to address all dimensions of your project and to reach the ambitious milestones required by the marketing of your product. Hereafter are the key people of Medidee.
GBS is the leading cause of life-threatening bacterial infections in newborn babies affecting some 8,000 babies annually in Europe and the US. GBS infections may result in still-births, or pneumonia, septicaemia and meningitis in the newborn babies leading to either severe morbidity, mortality or life-long disabilites. MinervaX is pursuing the development of a novel vaccine candidate against Group B Streptococci (GBS).
Nordic Nanovector is a biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers through the development and commercialisation of innovative targeted therapeutics.
The company's lead clinical-stage product is Betalutin®, the first in a new class of antibody radionuclide conjugates (ARCs), designed to improve upon and complement current options for the treatment of non-Hodgkin lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities.
Betalutin® is a tumour-seeking anti-CD37 antibody conjugated to a low-intensity radionuclide (lutetium-177). It is showing promising efficacy and tolerability in a Phase 1/2 clinical study in a difficult-to-treat NHL patient population.
The company aims to develop Betalutin® for the treatment of patients with relapsed/refractory NHL.
Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies.
Nordic Nanovector is committed to building a pipeline of novel ARCs and antibody drug conjugates (ADCs) addressing multiple selected haematological malignancies based on proprietary technologies and expertise, and with technologies from partners where complementary.
Our clients has dedicated their products, services or governance body to improve the life of patients.
Our business is to support all those of you who cares for the patients, to meet the patients needs, in any possible way. oi720 does quality consulting handcraft, with an agile and multidimensional mindset.
Multidimensional means addressing the constantly changing patient needs, without compromising patient safety, product/service quality and respecting legal, ethical and moral standards, hence the 720 degree view on any deliverable. That is possible due to industry experience combined with an innovative mindset.
The patient needs are fast moving, and we help the ecosystem around them to support those needs.
Ozack deliver value creating interactions with regulatory agencies during drug development.
• prepare regulatory strategies to discover the best path and mitigate risk
• explain ways of engaging regulators from early development and onwards
• take you through the regulatory steps with execution of required documents and leadership if needed
Papermill Medical is a globally operating medical and scientific consultancy that provides services for companies and organizations in the life science industries including pharma, biotech and diagnostics. Based on a proven track record in R&D and commercial functions of the pharmaceutical industry Papermill Medical can support clients in different tasks such as:
Patentgruppen rådgiver om IPR (Intellectual Property Rights), dvs. alt inden for patenter, brugsmodeller og designs. Patentgruppen ønsker at gøre det enkelt for dig at beskytte din forretning, produkter og innovation igennem en proaktiv og strategisk tilgang til IPR. Vi lader dig benytte alle vores tekniske og patentmæssige kompetencer ind i din virksomhed. Det bliver muligt, fordi vi arbejder i teams. Vi er både et team internt i Patentgruppen, men også et team med vores kunder. Uanset hvem du er og hvilke tekniske krav eller krav til IPR-viden, du har, så kan vi matche dit behov. Vi ser os selv som sparringspartner for vores kunder og vi er stolte over det arbejde, vi udfører.
Have you included data for price and reimbursement discussions in your clinical trials? To be able to document true 'value for money' the payer perspective must already be included in clinical trials from phase II. Pharma Evidence is your strategic partner specialized in health economics, outcome research and pricing. Contact us at +4530305526 for an informal discussion of how and when to secure optimal price and reimbursement at launch.
Creating low-bacterial environments.
At ACT.Global we help clients fight harmful microorganisms in a way that has not been seen before. Simple, clean and highly effective. We create a healthy indoor environment by eliminating three challenges that most companies face today: bacteria, air born pollutants and mould.
ReceptorPharma has the goal to develop new Alzheimer's drugs through a completely new pathway, mechanism and drug target. Our approach will lead to a new class of small molecule γ-secretase modulators (GSMs) without effect on Notch processing, thus circumventing one of the major obstacles that prior GSMs have been unable to overcome.
Red Glead Discovery
RefLab is a private Danish laboratory with extensive expertise in allergy and chronic urticaria testing, serving hospitals and allergy specialists. Further, we partner in projects within drug allergy and mechanisms of new anti-allergic drugs. In 2010 RefLab became a member of R-Biopharm group.
Region Hovedstadens Enhed for Forskning og Innovation
Centre for Innovation and Research (CIR) acts as a point of entry for issues relating to innovation and research and the commercialisation hereof in the Capital Region of Denmark. In addition to counselling and negotiating contracts, the centre actively leads projects to commercialise inventions and advises on clinical trials and funding. CIR also deals with strategic and political issues pertaining to innovation and research.
RetiPharma is a Biotech company focused on developing novel treatments for neurodegenerative eye diseases utilizing forward and backward translatability between animal models and patients.
Research conducted by scientists at the University of Copenhagen and the University Hospital founded RetiPharma advancing an NPY derived peptide as a candidate drug for preventing against vision associated with Retinal Detachment.
Reveal Consulting Denmark
The problem: Rheumatoid arthritis (RA) is a chronic debilitating disease with a high unmet medical need. Methotrexate (MTX) is the established cornerstone treatment of RA in all stages of the disease but has equally well-documented debilitating side effects which affects the vast majority of patients and in turn reduce MTX to a clinically viable treatment for a subsegment of RA patients, only.
The solution: Targeted-MTX has promise to deliver the well understood clinical benefits of the established “cornerstone” treatment(MTX)for RA without the equally documented debilitating side-effects.
The company: We have developed a targeted methotrexate (prodrug) that is designed for targeted release at the site of inflammation where high levels of ROS (reactive oxygen species) are present. MTX delivered as a proprietary molecule directly to the target with a game changing capability to disrupt and revolutionize the present treatment paradigm with a market potential of EUR 3.6 bn in RA in the US, EU and Japan.
Scan Medical Tech
LAB HOS is a company devoted to the design, develop and marketing of high-tech instruments for clinical testing and healthcare for labs and hospitals. We’re able to satisfy the exacting quality standards required by these industries thanks to the experience and expertise of our team. We are working in
- Lab section: we declare the best quality materials and high tech instrument to labs and IVO manufacturers, for example all reagents and instruments being used in immunoassay based clinical tests in medical and veterinary fields.
- Hospital section: we provide the EU approved facilities being used in patient caring like parts used in making bed hospital, different types of hospital and lab washing machines. Moreover, in clinical diagnostic section, we present PC based audiometers.
SoftOx Solutions AS is a Scandinavian medtech company, founded in 2012, after 4 years of research and product development.
The SoftOx technology, using acetic acid together with the body’s own disinfector, is developed by SoftOx Solutions AS with the support of leading chemical scientists from CR Competence at University of Lund, Sweden. In 2016, SoftOx Solutions established a partnership with Professor Thomas Bjarnsholt, Chief Surgeon Klaus Kirketerp-Møller, and the University of Copenhagen.
Scientists at University of Copenhagen have since 2007 conducted research on the use of acetic acid against biofilm, and since 2009 used acetic acid in clinical settings. The University of Copenhagen is a leading European research centre on biofilm and chronic wounds. SoftOx Solutions scientific department is established at the university under leadership of Thomas Bjarnsholt. Klaus Kirketerp-Møller will lead the company’s clinical research at Copenhagen University Hospital.
SOSmatematik er startet i 2012 af Jan Ulrich Lauridsen, som er uddannet cand.scient i matematik fra Københavns Universitet og til daglig underviser på Gammel Hellerup Gymnasium.
Formålet med SOSmatematik er at tilbyde hjælp til de mange gymnasieelever landet over, der oplever problemer med matematikundervisningen og har brug for et skub i den rigtige retning.
Dette gøres primært ved at arrangere kurser til attraktive priser, som kan tages uden for skoletiden - f.eks. i weekender og ferier.
ANALYSIS SYSTEM FOR REAL-TIME MEASUREMENTS
The Spectro Inlets analysis system incorporates our unique microchip inlet technology with a vacuum and gas-handling system in conjuction with a mass spectrometer to deliver unprecedented real-time measurements of dissolved gases in liquid environments. The analysis system can characterize minute gas evolution at the surface of an electrode for electrochemistry and battery R&D. As the inlet is robust and self-cleaning, the system is also suitable for monitoring dissolved gases for industrial applications such as biogas production and wastewater treatment.
We prevent chronic stress and treat your stress with mindfulness.
Individuals under high levels of pressure at work are 45 percent more likely to develop type 2 diabetes compared to those experiencing lower stress levels. According to WHO “Stress would be the main source of diseases by 2020". We are solving #1 problem of our society and while doing that, we are helping them by being happy.
The Back Office
Union Medico is a Developer and Manufacturer of Injectable Drug Delivery Systems. We are a trusted partner and we have been working with some of the world’s leading Biotech and Pharma companies for years. Our injection system is out there worldwide, millions of injections are now carried out with this injection system.
VAR2 Pharmaceuticals is a privately held biotechnology company engaged in the design and development of proprietary therapeutic proteins targeting cancer-specific carbohydrate structures for multiple cancer indications. We have a portfolio of proteins with unique affinity and specificity for these cancer-associated carbohydrates for the development of treatments for cancers where there is no effective therapy, such as sarcoma, triple negative breast cancers and prostate cancer.
The technology is based on groundbreaking discoveries made by researchers at University of Copenhagen, Denmark, in collaboration with partners at University of British Columbia, Canada.
Vild develops and markets safe, high quality products within children’s dermatology and supplements. Vild is pure and raw Nordic nature. We find raw materials and ingredients in the nature that surrounds us, and process them with an uncompromising attitude to quality and care. Simple and safe products for your child.
Scientific advice: In the area of pharmacology, toxicology and regulatory affairs - special focus on diabetes and veterinary medicine. Scientific reviews,safety/efficacy assessments, Drug development plans (screeningplans, CRO contact, project management with focus on translational medicine). Contract research: Pig glucose clamp model and general/ translational models for (diabetes) research in association with relevant CRO's.